Table 2 Main trials with tyrosine kinase inhibitors associated with radiotherapy in locally advanced SCCHN

Harrington K et al. [34]

RT + CDDP vs

5-yr 57.3%

RT + CDDP+ lapatinib

5-yr 56.6%

Martins RG et al. [35]

CDDP + RT vs

No difference

40%

2%

CDDP + RT+ erlotinib

52%

13%

Hainsworth JD et al. [19]

CBDCA + Tax + 5FU + beva → RT+ Tax + beva + erlotinib

3-yr 71%

3-yr 82%

88%

Yoo DS et al. [18]

Beva + erlotinib + CDDP + RT

3-yr 85%

3-yr 82%

3-yr 86%

48%

28%

Rao K et al. [36]

RT+ intra-arterial CDDP + erlotinib

1-yr 63%

Gregoire V et al. [37]

CDDP + RT vs

2-yr 33.6%

36%

13%

CDDP + RT + gefitinib +/− maint gefitinib

2-yr 32.7%

47%

5%

Cohen EE et al. [38]

FU + hydroxyurea + RT + gefitinib + 2-years maint gefitinib

4-yr 72%

4-yr 74%

33%

55%

Hainsworth JD et al. [48]

CBDCA + Doc + 5FU + gefitinib followed by RT + Doc + gefitinib and 2-years gefitinib

3-yr 41%

3-yr 54%

27%

Rodriguez CP et al. [49]

RT + CDDP + 5FU + gefitinib

+2-years gefitinib

3-yr 71%

87%